Pamela Demain

Pam recently retired from Merck & Co., Inc. and has over 35 years of experience in pharmaceutical business development, licensing, strategic planning and marketing. She previously served as Executive Director, Business Development and Licensing at Merck & Co., Inc. For the past 20 years, she was responsible for negotiating transactions with companies, universities and institutions worldwide, including arrangements for compounds, research collaborations, patents, formulations and research platform technologies. Prior, Ms. Demain was in charge of the Business Information & Research Department in the Worldwide Human Health Marketing area of Merck. She was also responsible for the worldwide launch of the antibiotic PRIMAXIN/TIENAM. She joined Merck in 1981 on a management training program. Ms. Demain is a graduate of the University of Massachusetts at Amherst, and holds a M.B.A. in International Business from The American University in Washington, D.C. and is a Certified Licensing Professional (CLP). She served as President, Licensing Executives Society USA and Canada (LES) 2014-2015 and was on the LES Board for over 10 years. She is a member of the ILSE Board of Trustees and was a member of the BioNJ Board from 2013-2016, heading the Membership Committee.